Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine

Author： Tsunoda T. Shibahara H. Hirano Y. Suzuki T. Fujiwara H. Takamizawa S. Ogawa S. Motoyama M. Suzuki M.

ISSN： 1473-0766

Source： Gynecological Endocrinology, Vol.17, Iss.4, 2003-08, pp. : 281-286

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cabergoline as treatment of ovarian hyperstimulation syndrome: a review

By Kalampokas Theodoros Creatsas George Kalampokas Emmanouil

Gynecological Endocrinology, Vol. 29, Iss. 2, 2013-02 ,pp. : 98-100

Informa Healthcare

Access to resources Recommend Favorite

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

By lvarez Claudio Alonso-Muriel Isabel Garca Gabriela Crespo Juana Bellver Jos Simn Carlos Pellicer Antonio

Human Reproduction, Vol. 22, Iss. 12, 2007-12 ,pp. : 3210-3214

Oxford University Press

Access to resources Recommend Favorite

Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study

By Hosseini Marzieh Agha Mahdavi Atossa Aleyasin Ashraf Safdarian Leili Bahmaee Fatemeh

Gynecological Endocrinology, Vol. 28, Iss. 11, 2012-11 ,pp. : 853-855

Informa Healthcare

Access to resources Recommend Favorite

Ovarian hyperstimulation syndrome

By Balen Adam

Human Fertility, Vol. 10, Iss. 3, 2007-09 ,pp. : 189-189

Informa Healthcare

Access to resources Recommend Favorite

Understanding ovarian hyperstimulation syndrome

By Delbaere Anne Smits Guillaume Leener Anne Costagliola Sabine Vassart Gilbert

Endocrine Journal, Vol. 26, Iss. 3, 2005-04 ,pp. : 285-289

Humana Press, Inc

Access to resources Recommend Favorite